Fig. 1: Validation of experimental approach to test effects of chronic oral sertraline in pregnancy. | Molecular Psychiatry

Fig. 1: Validation of experimental approach to test effects of chronic oral sertraline in pregnancy.

From: Peripartum sertraline impacts maternal neurobehavioral and neurodegenerative mechanisms in pregnant and postpartum mice

Fig. 1

A Experimental timeline. Gestational day, GD; Experimental day, ED. B Oral sertraline (167 mg/L oral suspension) increases sertraline in plasma to approximately 9 ng/mL via LC-MS/MS and (C) in amniotic fluid after drinking water sertraline administration in pregnancy to approximately 0.7 ng/mL, both at GD18. Sertraline dosing began 2 weeks prior to breeding, and (D, E) weight gains were apparent after only 2 weeks of sertraline dosing (experimental day 0). Two weeks of sertraline pre-breeding increased weight of dams by GD or ED 0, which persisted across ED 12, 18 in nonpregnant animals (two-way repeated measures [R.M.] ANOVA main effect [M.E.] of sertraline: F[1,27] = 11.83, p = 0.002) and GD 12 and 18 in pregnant animals (two-way R.M. ANOVA M.E. of sertraline: F[1,21] = 29.60, p < 0.0001). F Plasma 5-HT is increased across pregnancy and in particular at GD18 by post-hoc Holm t-test (q = 0.014).

Back to article page